#ISA2020 Yesterday: Plenery Session on Diagnosis and Management of AL #amyloidosis chaired by @awechalekar and Stefan Schönland. Here is my take home message @AmyloidosisSupp @Amyloidosisfdn @Amyloidosis_ARC @AmyloidC @MayoAmyloid @amyloid_papers
@ADispenzieri talked about Diagnosis and work-up. Fat pad biopsy and bone marrow biopsy are able to determine the diagnosis of AL in 50-79%. In those cases an organ biospy is not necessary
@ADispenzieri at #ISA2020: 10 % of patients with Congo Red+ amyloid detection have TTR Amyloidosis and elevated FLC--> you need to determine the diagnosis by mass spec or IHC
@ADispenzieri at #ISA2020: Clinical presentation of AL is very heterogenous --> look for the "Doors to amyloidosis diagnosis" with symptoms such as spinal stenosis, hepatomegaly or pseudoclaudication
Dr Hegenbart at #ISA2020 pointed out RED FLAGS 🚩for AL #amyloidosis and suggested NT-proBNP for all patients with MGUS and elevated Free Light Chins. NT-proBNP can detect cardiac involvement before symptoms of heart failure occur in 20% of patients.
Dr Kastritis presented at #ISA2020 data to use Growth Differentiation Factor-15 (GDF-15) as an independent prognostic marker for survival and renal outcomes in (AL) Amyloidosis
Dr Schönland at #ISA2020 t(11;14) is a negative prognostic marker for AL patients treated with bortezomib but a positive prognostic marker for patients receiving ASCT 🤔ASCT for all patients with t(11;14)?
Dr Schönland at #ISA2020 cytogenetic aberration impact prognosis in AL --> 1q21 gain has poorer prognosis in AL similar to MM. In t(11;14)consider venetoclax ASAP
Dr Palladini at #ISA2020 stated that decrease in IVS does not correlate with OS--> and should not ne used for organ response!
Dr Palladini at #ISA2020 summarised the goal for hematologic response--> Goal should be dFLC 10 or iFLC 20. Do not use FLC ratio in AL Amyloidosis

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Dr. Suzanne Lentzsch

Dr. Suzanne Lentzsch Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @SLentzsch

26 Nov 19
Looking forward to #ASH2019 in less than two weeks! Read the thread below for a list of 10 abstracts that I think offer new practice-changing insights, particularly for community oncologists . #leusm #mmsm
(1/10) Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Overall Survival in Alcyone
Abstract: ash.confex.com/ash/2019/webpr…
(2/10) Dara-KRd Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma
Abstract: ash.confex.com/ash/2019/webpr…
Read 11 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!